CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan

Stock News07-20

The biotechnology firm CLOVER BIO-B (02197) has issued a positive profit alert for the first half of the year.

For the six-month period ending June 30, 2026, the group expects to record a net profit in the range of approximately RMB 9.57 billion to RMB 12.04 billion.

This represents a significant reversal from the same period last year, which saw a net loss of about RMB 1.013 billion.

The primary driver behind this shift to profitability is an accounting gain of roughly RMB 10.89 billion to RMB 13.36 billion.

This gain stems from a settlement agreement entered into on March 22, 2026, between the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Limited, and Gavi.

Details of this settlement were previously disclosed in announcements released on March 22, 2026, and April 2, 2026.

The company's board of directors has emphasized that this accounting gain is of a non-recurring nature.

Excluding the impact of this one-time gain, the group is projected to continue recording a net loss for the six months ending June 30, 2026.

This underlying loss primarily reflects the group's ongoing investment in research and development activities and the absence of significant operational revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108650143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108650143","market":"other","top_or_hot":-1,"title":"CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan","media":"Stock News","content":"<p>The biotechnology firm <b>CLOVER BIO-B</b> (<b>02197</b>) has issued a positive profit alert for the first half of the year.<br><br>For the six-month period ending June 30, 2026, the group expects to record a net profit in the range of approximately RMB 9.57 billion to RMB 12.04 billion.<br><br>This represents a significant reversal from the same period last year, which saw a net loss of about RMB 1.013 billion.<br><br>The primary driver behind this shift to profitability is an accounting gain of roughly RMB 10.89 billion to RMB 13.36 billion.<br><br>This gain stems from a settlement agreement entered into on March 22, 2026, between the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Limited, and Gavi.<br><br>Details of this settlement were previously disclosed in announcements released on March 22, 2026, and April 2, 2026.<br><br>The company's board of directors has emphasized that this accounting gain is of a non-recurring nature.<br><br>Excluding the impact of this one-time gain, the group is projected to continue recording a net loss for the six months ending June 30, 2026.<br><br>This underlying loss primarily reflects the group's ongoing investment in research and development activities and the absence of significant operational revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The biotechnology firm <b>CLOVER BIO-B</b> (<b>02197</b>) has issued a positive profit alert for the first half of the year.<br><br>For the six-month period ending June 30, 2026, the group expects to record a net profit in the range of approximately RMB 9.57 billion to RMB 12.04 billion.<br><br>This represents a significant reversal from the same period last year, which saw a net loss of about RMB 1.013 billion.<br><br>The primary driver behind this shift to profitability is an accounting gain of roughly RMB 10.89 billion to RMB 13.36 billion.<br><br>This gain stems from a settlement agreement entered into on March 22, 2026, between the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Limited, and Gavi.<br><br>Details of this settlement were previously disclosed in announcements released on March 22, 2026, and April 2, 2026.<br><br>The company's board of directors has emphasized that this accounting gain is of a non-recurring nature.<br><br>Excluding the impact of this one-time gain, the group is projected to continue recording a net loss for the six months ending June 30, 2026.<br><br>This underlying loss primarily reflects the group's ongoing investment in research and development activities and the absence of significant operational revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1108650143","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108650143","pubTimestamp":1784502621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The biotechnology firm CLOVER BIO-B (02197) has issued a positive profit alert for the first half of the year.For the six-month period ending June 30, 2026, the group expects to record a net profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02197":"三叶草生物-B"},"translate_title":"三叶草生物-B预计年中利润扭亏为盈，预计净利润为95.7亿元至120.4亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"The biotechnology firm CLOVER BIO-B (02197) has issued a positive profit alert for the first half of the year.For the six-month period ending June 30, 2026, the group expects to record a net profit in the range of approximately RMB 9.57 billion to RMB 12.04 billion.This represents a significant reversal from the same period last year, which saw a net loss of about RMB 1.013 billion.The primary driver behind this shift to profitability is an accounting gain of roughly RMB 10.89 billion to RMB 13.36 billion.This gain stems from a settlement agreement entered into on March 22, 2026, between the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Limited, and Gavi.Details of this settlement were previously disclosed in announcements released on March 22, 2026, and April 2, 2026.The company's board of directors has emphasized that this accounting gain is of a non-recurring nature.Excluding the impact of this one-time gain, the group is projected to continue recording a net loss for the six months ending June 30, 2026.This underlying loss primarily reflects the group's ongoing investment in research and development activities and the absence of significant operational revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108650143","isCrawlerRequest":true}